Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.

Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00046. Epub 2017 May 31.

PMID:
30003184
2.

Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.

Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.

Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.

3.

Validation Strategy for Ultrasensitive Mutation Detection.

Debeljak M, Noë M, Riel SL, Haley LM, Norris AL, Anderson DA, Adams EM, Suenaga M, Beierl KF, Lin MT, Goggins MG, Gocke CD, Eshleman JR.

Mol Diagn Ther. 2018 Jul 5. doi: 10.1007/s40291-018-0350-z. [Epub ahead of print]

PMID:
29974360
4.

Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer.

Tamura K, Yu J, Hata T, Suenaga M, Shindo K, Abe T, MacGregor-Das A, Borges M, Wolfgang CL, Weiss MJ, He J, Canto MI, Petersen GM, Gallinger S, Syngal S, Brand RE, Rustgi A, Olson SH, Stoffel E, Cote ML, Zogopoulos G, Potash JB, Goes FS, McCombie RW, Zandi PP, Pirooznia M, Kramer M, Parla J, Eshleman JR, Roberts NJ, Hruban RH, Klein AP, Goggins M.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):4767-4772. doi: 10.1073/pnas.1720588115. Epub 2018 Apr 18.

PMID:
29669919
5.

No BRAF V600E Mutation Identified in 28 Periocular Pyogenic Granuloma.

Li G, Adams E, Eshleman JR, Eberhart CG.

Ophthalmic Plast Reconstr Surg. 2018 Feb 5. doi: 10.1097/IOP.0000000000001075. [Epub ahead of print]

PMID:
29406329
6.

Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid.

Hata T, Dal Molin M, McGregor-Das A, Song TJ, Wolfgang C, Eshleman JR, Hruban RH, Goggins M.

J Mol Diagn. 2018 Jan;20(1):46-55. doi: 10.1016/j.jmoldx.2017.09.006. Epub 2017 Dec 8.

PMID:
29229290
7.

Clinical mutational profiling of 1006 lung cancers by next generation sequencing.

Illei PB, Belchis D, Tseng LH, Nguyen D, De Marchi F, Haley L, Riel S, Beierl K, Zheng G, Brahmer JR, Askin FB, Gocke CD, Eshleman JR, Forde PM, Lin MT.

Oncotarget. 2017 May 20;8(57):96684-96696. doi: 10.18632/oncotarget.18042. eCollection 2017 Nov 14.

8.

Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.

Markowski MC, Silberstein JL, Eshleman JR, Eisenberger MA, Luo J, Antonarakis ES.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00127. Epub 2017 Oct 30.

9.

MSH2 Loss in Primary Prostate Cancer.

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL.

Clin Cancer Res. 2017 Nov 15;23(22):6863-6874. doi: 10.1158/1078-0432.CCR-17-0955. Epub 2017 Aug 8.

PMID:
28790115
10.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr.

Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.

11.

Haplotype Counting for Sensitive Chimerism Testing: Potential for Early Leukemia Relapse Detection.

Debeljak M, Mocci E, Morrison MC, Pallavajjalla A, Beierl K, Amiel M, Noë M, Wood LD, Lin MT, Gocke CD, Klein AP, Fuchs EJ, Jones RJ, Eshleman JR.

J Mol Diagn. 2017 May;19(3):427-436. doi: 10.1016/j.jmoldx.2017.01.005.

12.

Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas.

Wood LD, Noë M, Hackeng W, Brosens LA, Bhaijee F, Debeljak M, Yu J, Suenaga M, Singhi AD, Zaheer A, Boyce A, Robinson C, Eshleman JR, Goggins MG, Hruban RH, Collins MT, Lennon AM, Montgomery EA.

Virchows Arch. 2017 Apr;470(4):391-400. doi: 10.1007/s00428-017-2086-2. Epub 2017 Feb 10.

13.

Alterations of type II classical cadherin, cadherin-10 (CDH10), is associated with pancreatic ductal adenocarcinomas.

Jinawath N, Shiao MS, Norris A, Murphy K, Klein AP, Yonescu R, Iacobuzio-Donahue C, Meeker A, Jinawath A, Yeo CJ, Eshleman JR, Hruban RH, Brody JR, Griffin CA, Harada S.

Genes Chromosomes Cancer. 2017 May;56(5):427-435. doi: 10.1002/gcc.22447. Epub 2017 Mar 7.

PMID:
28124395
14.

Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting.

Lokhandwala PM, Riel SL, Haley L, Lu C, Chen Y, Silberstein J, Zhu Y, Zheng G, Lin MT, Gocke CD, Partin AW, Antonarakis ES, Luo J, Eshleman JR.

J Mol Diagn. 2017 Jan;19(1):115-125. doi: 10.1016/j.jmoldx.2016.08.003. Epub 2016 Dec 1.

PMID:
27916435
15.

Hypermutation In Pancreatic Cancer.

Humphris JL, Patch AM, Nones K, Bailey PJ, Johns AL, McKay S, Chang DK, Miller DK, Pajic M, Kassahn KS, Quinn MC, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Stone A, Wilson PJ, Anderson M, Fink JL, Holmes O, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Mead RS, Xu Q, Wu J, Pinese M, Cowley MJ, Jones MD, Nagrial AM, Chin VT, Chantrill LA, Mawson A, Chou A, Scarlett CJ, Pinho AV, Rooman I, Giry-Laterriere M, Samra JS, Kench JG, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, McKay CJ, Carter CR, Dickson EJ, Graham JS, Duthie F, Oien K, Hair J, Morton JP, Sansom OJ, Grützmann R, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Rusev B, Corbo V, Salvia R, Cataldo I, Tortora G, Tempero MA; Australian Pancreatic Cancer Genome Initiative, Hofmann O, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Gill AJ, Pearson JV, Grimmond SM, Waddell N, Biankin AV.

Gastroenterology. 2017 Jan;152(1):68-74.e2. doi: 10.1053/j.gastro.2016.09.060. Epub 2016 Nov 15.

PMID:
27856273
16.

Morphology and genetics of pyloric gland adenomas in familial adenomatous polyposis.

Hackeng WM, Montgomery EA, Giardiello FM, Singhi AD, Debeljak M, Eshleman JR, Vieth M, Offerhaus GJ, Wood LD, Brosens LA.

Histopathology. 2017 Mar;70(4):549-557. doi: 10.1111/his.13105. Epub 2016 Dec 13.

17.

Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.

Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES.

Prostate. 2016 Dec;76(16):1484-1490. doi: 10.1002/pros.23232. Epub 2016 Jul 12.

18.

Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective.

Chen G, Yang Z, Eshleman JR, Netto GJ, Lin MT.

Biomed Res Int. 2016;2016:9850690. Epub 2016 Sep 6. Review.

19.

A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts.

Masica DL, Dal Molin M, Wolfgang CL, Tomita T, Ostovaneh MR, Blackford A, Moran RA, Law JK, Barkley T, Goggins M, Irene Canto M, Pittman M, Eshleman JR, Ali SZ, Fishman EK, Kamel IR, Raman SP, Zaheer A, Ahuja N, Makary MA, Weiss MJ, Hirose K, Cameron JL, Rezaee N, He J, Joon Ahn Y, Wu W, Wang Y, Springer S, Diaz LL Jr, Papadopoulos N, Hruban RH, Kinzler KW, Vogelstein B, Karchin R, Lennon AM.

J Am Med Inform Assoc. 2017 Jan;24(1):145-152. doi: 10.1093/jamia/ocw069. Epub 2016 Jun 21.

20.

Heterogeneity of resistance mutations detectable by nextgeneration sequencing in TKI-treated lung adenocarcinoma.

Belchis DA, Tseng LH, Gniadek T, Haley L, Lokhandwala P, Illei P, Gocke CD, Forde P, Brahmer J, Askin FB, Eshleman JR, Lin MT.

Oncotarget. 2016 Jul 19;7(29):45237-45248. doi: 10.18632/oncotarget.9931.

21.

Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing.

Zheng G, Lin MT, Lokhandwala PM, Beierl K, Netto GJ, Gocke CD, Eshleman JR, McCarthy E, Illei PB.

Cancer Cytopathol. 2016 Oct;124(10):744-753. doi: 10.1002/cncy.21743. Epub 2016 Jun 10.

22.

Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens.

Zheng G, Tsai H, Tseng LH, Illei P, Gocke CD, Eshleman JR, Netto G, Lin MT.

Am J Clin Pathol. 2016 May;145(5):696-702. doi: 10.1093/ajcp/aqw043.

PMID:
27247373
23.

Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation.

Gondek LP, Zheng G, Ghiaur G, DeZern AE, Matsui W, Yegnasubramanian S, Lin MT, Levis M, Eshleman JR, Varadhan R, Tucker N, Jones R, Gocke CD.

Leukemia. 2016 Sep;30(9):1916-1920. doi: 10.1038/leu.2016.63. Epub 2016 Mar 15. No abstract available.

24.

Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.

Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, McAlexander M, Dy B, Sorensen M, Aronova A, Sebo TJ, Giordano TJ, Fahey TJ 3rd, Thompson GB, Gauger PG, Somervell H, Bishop JA, Eshleman JR, Schneider EB, Witwer KW, Umbricht CB, Zeiger MA.

Thyroid. 2016 Apr;26(4):532-42. doi: 10.1089/thy.2015.0378. Epub 2016 Mar 7.

25.

Genomic analyses identify molecular subtypes of pancreatic cancer.

Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrill LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Lovell JA, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Moran-Jones K, Jamieson NB, Graham JS, Duthie F, Oien K, Hair J, Grützmann R, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P, Salvia R, Tortora G, Mukhopadhyay D, Petersen GM; Australian Pancreatic Cancer Genome Initiative, Munzy DM, Fisher WE, Karim SA, Eshleman JR, Hruban RH, Pilarsky C, Morton JP, Sansom OJ, Scarpa A, Musgrove EA, Bailey UM, Hofmann O, Sutherland RL, Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Waddell N, Biankin AV, Grimmond SM.

Nature. 2016 Mar 3;531(7592):47-52. doi: 10.1038/nature16965. Epub 2016 Feb 24.

PMID:
26909576
26.

Microsatellite Instability as a Biomarker for PD-1 Blockade.

Dudley JC, Lin MT, Le DT, Eshleman JR.

Clin Cancer Res. 2016 Feb 15;22(4):813-20. doi: 10.1158/1078-0432.CCR-15-1678. Review.

27.

Nanopore sequencing detects structural variants in cancer.

Norris AL, Workman RE, Fan Y, Eshleman JR, Timp W.

Cancer Biol Ther. 2016;17(3):246-53. doi: 10.1080/15384047.2016.1139236. Epub 2016 Jan 19.

28.

Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer.

Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, Kurtz RC, Olson SH, Rustgi AK, Schwartz AG, Stoffel E, Syngal S, Zogopoulos G, Ali SZ, Axilbund J, Chaffee KG, Chen YC, Cote ML, Childs EJ, Douville C, Goes FS, Herman JM, Iacobuzio-Donahue C, Kramer M, Makohon-Moore A, McCombie RW, McMahon KW, Niknafs N, Parla J, Pirooznia M, Potash JB, Rhim AD, Smith AL, Wang Y, Wolfgang CL, Wood LD, Zandi PP, Goggins M, Karchin R, Eshleman JR, Papadopoulos N, Kinzler KW, Vogelstein B, Hruban RH, Klein AP.

Cancer Discov. 2016 Feb;6(2):166-75. doi: 10.1158/2159-8290.CD-15-0402. Epub 2015 Dec 9.

29.

Mutational profiling of colorectal cancers with microsatellite instability.

Lin EI, Tseng LH, Gocke CD, Reil S, Le DT, Azad NS, Eshleman JR.

Oncotarget. 2015 Dec 8;6(39):42334-44. doi: 10.18632/oncotarget.5997.

30.

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF.

Zheng G, Tseng LH, Chen G, Haley L, Illei P, Gocke CD, Eshleman JR, Lin MT.

BMC Cancer. 2015 Oct 24;15:779. doi: 10.1186/s12885-015-1811-y.

31.

Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool.

Carter J, Tseng LH, Zheng G, Dudley J, Illei P, Gocke CD, Eshleman JR, Lin MT.

Am J Clin Pathol. 2015 Oct;144(4):620-8. doi: 10.1309/AJCP85ATMJOZOUDJ.

PMID:
26386083
32.

A combination of molecular markers and clinical features improve the classification of pancreatic cysts.

Springer S, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Niknafs N, Douville C, Ptak J, Dobbyn L, Allen PJ, Klimstra DS, Schattner MA, Schmidt CM, Yip-Schneider M, Cummings OW, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang JY, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, Weiss MJ, Cameron J, Pittman M, Eshleman JR, Diaz LA Jr, Papadopoulos N, Kinzler KW, Karchin R, Hruban RH, Vogelstein B, Lennon AM.

Gastroenterology. 2015 Nov;149(6):1501-10. doi: 10.1053/j.gastro.2015.07.041. Epub 2015 Aug 4.

33.

Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.

Haley L, Tseng LH, Zheng G, Dudley J, Anderson DA, Azad NS, Gocke CD, Eshleman JR, Lin MT.

Mod Pathol. 2015 Oct;28(10):1390-9. doi: 10.1038/modpathol.2015.86. Epub 2015 Jul 31.

34.

Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients.

Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, O'Dwyer PJ, Allen PJ, Eshleman JR, Thompson CB, Klimstra DS, Linehan DC, Maitra A, Hruban RH, Diaz LA Jr, Von Hoff DD, Johansen JS, Drebin JA, Velculescu VE.

Nat Commun. 2015 Jul 7;6:7686. doi: 10.1038/ncomms8686.

35.

Software-Based Pyrogram® Evaluation.

Chen G, Olson MT, Eshleman JR.

Methods Mol Biol. 2015;1315:29-38. doi: 10.1007/978-1-4939-2715-9_3.

PMID:
26103889
36.

Transflip mutations produce deletions in pancreatic cancer.

Norris AL, Kamiyama H, Makohon-Moore A, Pallavajjala A, Morsberger LA, Lee K, Batista D, Iacobuzio-Donahue CA, Lin MT, Klein AP, Hruban RH, Wheelan SJ, Eshleman JR.

Genes Chromosomes Cancer. 2015 Aug;54(8):472-481. doi: 10.1002/gcc.22258. Epub 2015 May 29.

37.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr.

N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.

38.

Whole genomes redefine the mutational landscape of pancreatic cancer.

Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Waddell N, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA; Australian Pancreatic Cancer Genome Initiative, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM.

Nature. 2015 Feb 26;518(7540):495-501. doi: 10.1038/nature14169.

39.

Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers.

Dudley J, Tseng LH, Rooper L, Harris M, Haley L, Chen G, Gocke CD, Eshleman JR, Lin MT.

Arch Pathol Lab Med. 2015 Feb;139(2):211-8. doi: 10.5858/arpa.2013-0649-OA.

PMID:
25611103
40.

KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound.

Eshleman JR, Norris AL, Sadakari Y, Debeljak M, Borges M, Harrington C, Lin E, Brant A, Barkley T, Almario JA, Topazian M, Farrell J, Syngal S, Lee JH, Yu J, Hruban RH, Kanda M, Canto MI, Goggins M.

Clin Gastroenterol Hepatol. 2015 May;13(5):963-9.e4. doi: 10.1016/j.cgh.2014.11.028. Epub 2014 Dec 4.

41.

Lymph node metastases of melanoma: challenges for BRAF mutation detection.

Chen G, Dudley J, Tseng LH, Smith K, Gurda GT, Gocke CD, Eshleman JR, Lin MT.

Hum Pathol. 2015 Jan;46(1):113-9. doi: 10.1016/j.humpath.2014.09.014. Epub 2014 Oct 7.

PMID:
25456393
42.

Advancements in the development of HIF-1α-activated protein switches for use in enzyme prodrug therapy.

Wright RC, Khakhar A, Eshleman JR, Ostermeier M.

PLoS One. 2014 Nov 26;9(11):e114032. doi: 10.1371/journal.pone.0114032. eCollection 2014.

43.

PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.

Rodić N, Anders RA, Eshleman JR, Lin MT, Xu H, Kim JH, Beierl K, Chen S, Luber BS, Wang H, Topalian SL, Pardoll DM, Taube JM.

Cancer Immunol Res. 2015 Feb;3(2):110-5. doi: 10.1158/2326-6066.CIR-14-0145. Epub 2014 Nov 4.

44.

Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.

Grunwald MR, Tseng LH, Lin MT, Pratz KW, Eshleman JR, Levis MJ, Gocke CD.

Biol Blood Marrow Transplant. 2014 Dec;20(12):1989-95. doi: 10.1016/j.bbmt.2014.08.015. Epub 2014 Aug 23.

45.

Familial and sporadic pancreatic cancer share the same molecular pathogenesis.

Norris AL, Roberts NJ, Jones S, Wheelan SJ, Papadopoulos N, Vogelstein B, Kinzler KW, Hruban RH, Klein AP, Eshleman JR.

Fam Cancer. 2015 Mar;14(1):95-103. doi: 10.1007/s10689-014-9755-y.

46.

Haplotype counting by next-generation sequencing for ultrasensitive human DNA detection.

Debeljak M, Freed DN, Welch JA, Haley L, Beierl K, Iglehart BS, Pallavajjala A, Gocke CD, Leffell MS, Lin MT, Pevsner J, Wheelan SJ, Eshleman JR.

J Mol Diagn. 2014 Sep;16(5):495-503. doi: 10.1016/j.jmoldx.2014.04.003. Erratum in: J Mol Diagn. 2015 Nov;17(6):749.

47.

Cytosine deamination is a major cause of baseline noise in next-generation sequencing.

Chen G, Mosier S, Gocke CD, Lin MT, Eshleman JR.

Mol Diagn Ther. 2014 Oct;18(5):587-93. doi: 10.1007/s40291-014-0115-2.

48.

False positives in multiplex PCR-based next-generation sequencing have unique signatures.

McCall CM, Mosier S, Thiess M, Debeljak M, Pallavajjala A, Beierl K, Deak KL, Datto MB, Gocke CD, Lin MT, Eshleman JR.

J Mol Diagn. 2014 Sep;16(5):541-549. doi: 10.1016/j.jmoldx.2014.06.001. Epub 2014 Jul 11.

49.

Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.

Lin MT, Mosier SL, Thiess M, Beierl KF, Debeljak M, Tseng LH, Chen G, Yegnasubramanian S, Ho H, Cope L, Wheelan SJ, Gocke CD, Eshleman JR.

Am J Clin Pathol. 2014 Jun;141(6):856-66. doi: 10.1309/AJCPMWGWGO34EGOD.

50.

BRAF pyrosequencing analysis aided by a lookup table.

Olson MT, Harrington C, Beierl K, Chen G, Thiess M, O'Neill A, Taube JM, Zeiger MA, Lin MT, Eshleman JR.

Am J Clin Pathol. 2014 May;141(5):639-47. doi: 10.1309/AJCPVWH1K2ZIHHTV.

Supplemental Content

Loading ...
Support Center